
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1326109/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis. JAMA - Journal of the American Medical Association, 2012, 308, 2584.	3.8	1,327
2	Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet, The, 2005, 365, 123-129.	6.3	1,105
3	Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid. Gastroenterology, 2009, 136, 1281-1287.	0.6	387
4	Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b. Gastroenterology, 2008, 135, 459-467.	0.6	373
5	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. Gastroenterology, 2014, 147, 1338-1349.e5.	0.6	365
6	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology, 2017, 152, 1975-1984.e8.	0.6	355
7	Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa. Gastroenterology, 2009, 137, 2002-2009.	0.6	349
8	Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology, 2004, 39, 804-810.	3.6	321
9	Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology, 2004, 39, 500-508.	3.6	315
10	Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology, 2008, 47, 1856-1862.	3.6	262
11	Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology, 2010, 52, 1251-1257.	3.6	259
12	Comparison of echocardiographic methods with magnetic resonance imaging for assessment of right ventricular function in children. American Journal of Cardiology, 1995, 76, 589-594.	0.7	250
13	Treatment with Peg-Interferon alpha-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype. American Journal of Gastroenterology, 2006, 101, 297-303.	0.2	249
14	Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Journal of Hepatology, 1997, 26, 961-966.	1.8	219
15	External Validation of the Fatty Liver Index for Identifying Nonalcoholic Fatty Liver Disease in a Population-based Study. Clinical Gastroenterology and Hepatology, 2013, 11, 1201-1204.	2.4	218
16	Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology, 2010, 52, 454-461.	3.6	215
17	Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology, 2013, 58, 872-880.	3.6	201
18	Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: Results from the Rotterdam study. Journal of Hepatology, 2012, 57, 1305-1311.	1.8	198

#	Article	IF	CITATIONS
19	Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut, 2014, 63, 292-299.	6.1	195
20	Nucleos(t)ide Analogues Only Induce Temporary Hepatitis B e Antigen Seroconversion in Most Patients With Chronic Hepatitis B. Gastroenterology, 2010, 139, 491-498.	0.6	180
21	Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respiratory Medicine,the, 2021, 9, 498-510.	5.2	180
22	Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut, 2015, 64, 1289-1295.	6.1	178
23	Quantification of right ventricular function with magnetic resonance imaging in children with normal hearts and with congenital heart disease. American Heart Journal, 1995, 130, 828-837.	1.2	173
24	Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B. Gastroenterology, 2012, 142, 513-520.e1.	0.6	171
25	A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. Journal of Virological Methods, 2003, 110, 201-209.	1.0	161
26	Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut, 2013, 62, 760-765.	6.1	159
27	Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. Journal of Hepatology, 2012, 56, 1006-1011.	1.8	155
28	Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naÃ ⁻ ve patients with a partial virological response. Hepatology, 2011, 54, 443-451.	3.6	150
29	Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials. Gastroenterology, 1999, 117, 408-413.	0.6	146
30	International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. Journal of Hepatology, 2005, 43, 250-257.	1.8	143
31	Prognosis of Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cirrhosis. Results of a 10-Yr Cohort Study Involving 297 Patients. American Journal of Gastroenterology, 2006, 101, 2044-2050.	0.2	143
32	Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. Journal of Hepatology, 2011, 54, 449-454.	1.8	134
33	Long-term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus. Gastroenterology, 2010, 139, 1934-1941.	0.6	123
34	Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss. Journal of Infectious Diseases, 2011, 204, 415-418.	1.9	122
35	A randomized comparison of electrocautery incision with Savary bougienage for relief of anastomotic gastroesophageal strictures. Gastrointestinal Endoscopy, 2009, 70, 849-855.	0.5	110
36	Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology, 2007, 46, 388-394.	3.6	107

#	Article	IF	CITATIONS
37	Time-varying intensity of mechanical ventilation and mortality in patients with acute respiratory failure: a registry-based, prospective cohort study. Lancet Respiratory Medicine,the, 2020, 8, 905-913.	5.2	106
38	The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: Results of a double-blind, randomized, placebo-controlled trial. Hepatology, 2010, 52, 1334-1340.	3.6	104
39	Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues. Journal of Hepatology, 2010, 52, 493-500.	1.8	103
40	Prior radiation and/or chemotherapy has no effect on the outcome of metal stent placement for oesophagogastric carcinoma. European Journal of Gastroenterology and Hepatology, 2004, 16, 163-170.	0.8	98
41	Metastases in Supraclavicular Lymph Nodes in Lung Cancer: Assessment with Palpation, US, and CT. Radiology, 2004, 232, 75-80.	3.6	97
42	Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals. Gastroenterology, 2018, 154, 515-517.e3.	0.6	96
43	A Randomized Trial of Peginterferon α-2a With or Without Ribavirin for HBeAg-Negative Chronic Hepatitis B. American Journal of Gastroenterology, 2010, 105, 1762-1769.	0.2	83
44	Serum liver enzymes are associated with all ause mortality in an elderly population. Liver International, 2014, 34, 296-304.	1.9	83
45	Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. Journal of Hepatology, 1999, 30, 192-198.	1.8	80
46	Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: A randomized phase II trial. Journal of Hepatology, 2006, 45, 539-546.	1.8	76
47	Histological differentiation grade and microvascular invasion of hepatocellular carcinoma predicted by dynamic contrastâ€enhanced MRI. Journal of Magnetic Resonance Imaging, 2012, 36, 641-647.	1.9	76
48	Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. The Lancet Gastroenterology and Hepatology, 2020, 5, 649-657.	3.7	76
49	Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Hepatology, 2012, 56, 67-75.	3.6	75
50	Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. Journal of Hepatology, 2002, 37, 137-144.	1.8	70
51	Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. Journal of Hepatology, 2010, 53, 468-476.	1.8	68
52	Hepatitis B Surface Antigen Declines and Clearance During Long-Term Tenofovir Therapy in Patients Coinfected With HBV and HIV. Journal of Infectious Diseases, 2012, 206, 974-980.	1.9	68
53	Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis <scp>B</scp> and <scp>C</scp> . Liver International, 2012, 32, 622-628.	1.9	68
54	Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation. Journal of Hepatology, 2019, 70, 666-673.	1.8	66

#	Article	IF	CITATIONS
55	Increased incidence of early <i>de novo</i> cancer in liver graft recipients treated with cyclosporine: An association with C ₂ monitoring and recipient age. Liver Transplantation, 2010, 16, 837-846.	1.3	65
56	Histological features in western patients with idiopathic non irrhotic portal hypertension. Histopathology, 2013, 62, 1083-1091.	1.6	65
57	Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2021, 19, 463-472.	2.4	64
58	Patterns of viral decline during PEC-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response. Hepatology, 2006, 44, 721-727.	3.6	63
59	Durable Hepatitis B Surface Antigen Decline in Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Treated with Pegylated Interferon-α2B: Relation to Response and HBV Genotype. Antiviral Therapy, 2012, 17, 9-17.	0.6	63
60	Generic and disease-specific health related quality of life in non-cirrhotic, cirrhotic and transplanted liver patients: a cross-sectional study. BMC Gastroenterology, 2003, 3, 33.	0.8	62
61	A Prospective Open Study of the Efficacy of Highâ€Dose Recombinant Hepatitis B Rechallenge Vaccination in HIVâ€Infected Patients. Journal of Infectious Diseases, 2008, 197, 292-294.	1.9	62
62	Volume Measurements of the Anal Sphincter Complex in Healthy Controls and Fecal-Incontinent Patients With a Three-Dimensional Reconstruction of Endoanal Ultrasonography Images. Diseases of the Colon and Rectum, 2005, 48, 540-548.	0.7	57
63	Endoscopic visible light spectroscopy: a new, minimally invasive technique to diagnose chronic GI ischemia. Gastrointestinal Endoscopy, 2011, 73, 291-298.	0.5	56
64	Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]. BMC Gastroenterology, 2004, 4, 13.	0.8	54
65	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2076-2084.e2.	2.4	54
66	MicroRNA profiles in graft preservation solution are predictive of ischemic-type biliary lesions after liver transplantation. Journal of Hepatology, 2013, 59, 1231-1238.	1.8	52
67	The Liver Disease Symptom Index 2.0; Validation of a Disease-Specific Questionnaire. Quality of Life Research, 2004, 13, 1469-1481.	1.5	51
68	Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology, 2010, 52, 1225-1231.	3.6	50
69	US and Fluoroscopic-guided Percutaneous Jejunostomy: Experience in 49 Patients. Journal of Vascular and Interventional Radiology, 2000, 11, 101-106.	0.2	49
70	A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. Journal of Clinical Virology, 2011, 51, 175-178.	1.6	49
71	Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. Scandinavian Journal of Gastroenterology, 2011, 46, 962-972.	0.6	48
72	Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. Vaccine, 2013, 31, 1040-1044.	1.7	48

#	Article	IF	CITATIONS
73	Endoscopic treatment of esophagogastric variceal bleeding in patients with noncirrhotic extrahepatic portal vein thrombosis: a long-term follow-up study. Gastrointestinal Endoscopy, 2008, 67, 821-827.	0.5	46
74	Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Journal of Hepatology, 2010, 53, 455-459.	1.8	46
75	Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. Journal of Hepatology, 2013, 58, 898-903.	1.8	46
76	Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVIDâ€19: A singleâ€center prospective longitudinal study. Journal of Thrombosis and Haemostasis, 2021, 19, 1546-1557.	1.9	45
77	Longâ€term outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in Budd–Chiari syndrome. Liver International, 2008, 28, 249-256.	1.9	44
78	The cervical spine in rheumatoid arthritis: relationship between neurologic signs and morphology on MR imaging and radiographs. Skeletal Radiology, 1996, 25, 113-118.	1.2	43
79	Predictors of Treatment Failure for Hip and Knee Prosthetic Joint Infections in the Setting of 1- and 2-Stage Exchange Arthroplasty: A Multicenter Retrospective Cohort. Open Forum Infectious Diseases, 2019, 6, ofz452.	0.4	43
80	Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. Journal of Hepatology, 1998, 28, 951-959.	1.8	41
81	Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patientsâ~†. Journal of Hepatology, 2004, 40, 689-695.	1.8	41
82	Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Journal of Hepatology, 1999, 31, 256-262.	1.8	40
83	Immunoglobulin G4-related Prostatitis: A Case-control Study Focusing on Clinical andÂPathologic Characteristics. Urology, 2014, 83, 521-527.	0.5	40
84	Is there sufficient evidence to recommend antiviral therapy in hepatitis C?. Journal of Hepatology, 2014, 60, 191-196.	1.8	40
85	Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. Journal of Medical Virology, 2007, 79, 1055-1063.	2.5	39
86	Prediction of the response to pegâ€interferonâ€alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. Journal of Medical Virology, 2010, 82, 1135-1142.	2.5	39
87	Generic and disease-specific health related quality of life of liver patients with various aetiologies: A survey. Quality of Life Research, 2007, 16, 375-388.	1.5	37
88	Comparable Efficacy of Low- Versus High-Dose Induction Corticosteroid Treatment in Autoimmune Pancreatitis. Pancreas, 2014, 43, 261-267.	0.5	37
89	Is Textbook Outcome a valuable composite measure for short-term outcomes of gastrointestinal treatments in the Netherlands using hospital information system data? <i>A retrospective cohort study</i> . BMJ Open, 2018, 8, e019405.	0.8	37
90	Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. Scandinavian Journal of Gastroenterology, 2006, 41, 1087-1094.	0.6	36

#	Article	IF	CITATIONS
91	Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. European Journal of Gastroenterology and Hepatology, 2010, 22, 1.	0.8	36
92	Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2018, 16, 1098-1105.e1.	2.4	35
93	Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008. BMC Gastroenterology, 2010, 10, 144.	0.8	34
94	A Randomized Controlled Study of Accelerated Versus Standard Hepatitis B Vaccination in HIV-Positive Patients. Journal of Infectious Diseases, 2011, 203, 984-991.	1.9	34
95	Close Monitoring of Hepatitis B Surface Antigen Levels Helps Classify Flares During Peginterferon Therapy and Predicts Treatment Response. Clinical Infectious Diseases, 2013, 56, 100-105.	2.9	34
96	Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin. Journal of Hepatology, 2001, 34, 435-440.	1.8	33
97	Viral dynamics in chronic hepatitis B patients during lamivudine therapy. Liver, 2002, 22, 121-126.	0.1	33
98	Paired, quantitative measurements of hepatitis B virus DNA in saliva, urine and serum of chronic hepatitis B patients. European Journal of Gastroenterology and Hepatology, 2005, 17, 1173-1179.	0.8	33
99	The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine. Journal of Hepatology, 2002, 37, 253-258.	1.8	31
100	?-Glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-?-2b in chronic hepatitis C non-responders. Liver International, 2007, 27, 070816165951003-???.	1.9	30
101	Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. BMC Gastroenterology, 2012, 12, 11.	0.8	30
102	Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. Gut, 2015, 64, 322-331.	6.1	30
103	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1688-1697.e14.	2.4	30
104	Update on PADI trial: Percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia. Journal of Vascular Surgery, 2009, 50, 687-689.	0.6	28
105	Serum Markers and Intestinal Mucosal Injury in Chronic Gastrointestinal Ischemia. Digestive Diseases and Sciences, 2011, 56, 506-512.	1.1	28
106	Successful Treatment with Peginterferon alfa-2b of HBeAg-positive HBV Non-Responders to Standard Interferon or Lamivudine. American Journal of Gastroenterology, 2006, 101, 2523-2529.	0.2	27
107	Early HBeAg Loss During Peginterferon α-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients. American Journal of Gastroenterology, 2009, 104, 2449-2457.	0.2	27
108	Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis. Journal of Hepatology, 2019, 71, 992-999.	1.8	25

#	Article	IF	CITATIONS
109	Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine–famciclovir or lamivudine–ganciclovir. European Journal of Gastroenterology and Hepatology, 2002, 14, 1007-1011.	0.8	24
110	Potent Immune Activation in Chronic Hepatitis C Patients upon Administration of An Oral Inducer of Endogenous Interferons that Acts via Toll-Like Receptor 7. Antiviral Therapy, 2012, 17, 657-667.	0.6	24
111	Functional single-nucleotide polymorphism of epidermal growth factor is associated with the development of Barrett's esophagus and esophageal adenocarcinoma. Journal of Human Genetics, 2012, 57, 26-32.	1.1	24
112	Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis. Liver International, 2021, 41, 535-544.	1.9	23
113	Discriminant analysis using a multivariate linear mixed model with a normal mixture in the random effects distribution. Statistics in Medicine, 2010, 29, 3267-3283.	0.8	22
114	Use of Visible Light Spectroscopy to Diagnose Chronic Gastrointestinal Ischemia and Predict Response to Treatment. Clinical Gastroenterology and Hepatology, 2015, 13, 122-130.e1.	2.4	22
115	Primary Sclerosing Cholangitis in Children With Inflammatory Bowel Diseases Is Associated With Milder Clinical Activity But More Frequent Subclinical Inflammation and Growth Impairment. Clinical Gastroenterology and Hepatology, 2020, 18, 1509-1517.e7.	2.4	22
116	Drug Therapies for Ulcerative Proctitis. Inflammatory Bowel Diseases, 2014, 20, 2157-2178.	0.9	21
117	Pretreatment Intrahepatic CD8+Cell Count Correlates with Virological Response to Antiviral Therapy in Chronic Hepatitis C Virus Infection. Journal of Infectious Diseases, 2003, 188, 1528-1532.	1.9	20
118	Integrity of the Anal Sphincters After Pouch-Anal Anastomosis: Evaluation With Three-Dimensional Endoanal Ultrasonography. Diseases of the Colon and Rectum, 2005, 48, 1728-1735.	0.7	20
119	Neuroenteric peptides affect natural killer activity by intestinal lamina propria mononuclear cells. Journal of Neuroimmunology, 1993, 42, 139-145.	1.1	18
120	A Comparative Study of Diagnostic Scoring Systems for Autoimmune Pancreatitis. Pancreas, 2014, 43, 559-564.	0.5	18
121	Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. Journal of Hepatology, 2014, 61, 482-491.	1.8	18
122	<i>Nco</i> I TNF-β gene polymorphism and TNF expression are associated with an increased risk of developing Barrett's esophagus and esophageal adenocarcinoma. Scandinavian Journal of Gastroenterology, 2012, 47, 378-386.	0.6	17
123	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 684-692.e6.	2.4	17
124	Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]. BMC Gastroenterology, 2003, 3, 24.	0.8	16
125	Hepatitis B e antigen levels and response to peginterferon: Influence of precore and basal core promoter mutants. Antiviral Research, 2013, 97, 312-317.	1.9	16
126	Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program. Gastroenterology, 2018, 155, 1392-1399.e5.	0.6	16

#	Article	IF	CITATIONS
127	Pegylated Interferon Results in Higher Serological, but Not Virological, Response Rates When Compared to Continuous Entecavir. Antiviral Therapy, 2012, 17, 1605-1608.	0.6	15
128	Heterotopic vs. orthotopic liver transplantation for chronic liver disease: A case-control comparison of short-term and long-term outcomes. Liver Transplantation, 2005, 11, 396-401.	1.3	14
129	Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection. Clinical Gastroenterology and Hepatology, 2021, 19, 1933-1940.e1.	2.4	14
130	Evaluation of quantitative MRCP (MRCP+) for risk stratification of primary sclerosing cholangitis: comparison with morphological MRCP, MR elastography, and biochemical risk scores. European Radiology, 2022, 32, 67-77.	2.3	14
131	Renal Dysfunction After Liver Transplantation: Effect of Donor Type. Liver Transplantation, 2020, 26, 799-810.	1.3	13
132	Reducing Read Time of Point-of-Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNA. Clinical Gastroenterology and Hepatology, 2021, 19, 1451-1458.e4.	2.4	12
133	The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. Transplantation, 2020, 104, 2087-2096.	0.5	12
134	Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α-2a. European Journal of Gastroenterology and Hepatology, 2012, 24, 1012-1019.	0.8	11
135	Pediatric Wilson Disease Presenting as Acute Liver Failure. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, e90-e96.	0.9	11
136	Trends in indications and outcomes of liver transplantation in Canada: A multicenter retrospective study. Transplant International, 2021, 34, 1444-1454.	0.8	11
137	Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation. Pharmacogenetics and Genomics, 2014, 24, 427-435.	0.7	10
138	Risk stratification and prognostic modelling in primary biliary cholangitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 34-35, 95-106.	1.0	10
139	Internal medicine hospitalisations and liver disease: a comparative disease burden analysis of a multicentre cohort. Alimentary Pharmacology and Therapeutics, 2021, 54, 689-698.	1.9	8
140	Levels of Antibodies to Hepatitis B Core Antigen Are Associated With Liver Inflammation and Response to Peginterferon in Patients With Chronic Hepatitis B. Journal of Infectious Diseases, 2022, 227, 113-122.	1.9	8
141	Identification of prosthetic hip and knee joint infections using administrative databases—A validation study. Infection Control and Hospital Epidemiology, 2021, 42, 325-330.	1.0	7
142	The Impact of Primary Liver Disease and Social Determinants in a Mixed Donor Liver Transplant Program: A Single enter Analysis. Liver Transplantation, 2021, 27, 1733-1746.	1.3	7
143	Clinical outcome after cyclosporine dose reduction based on C2 levels in long-term liver transplant patients. Clinical Transplantation, 2005, 19, 537-542.	0.8	6
144	Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at day 0, day 22, day 29, and week 6. Hepatology, 2007, 45, 258-259.	3.6	6

#	Article	IF	CITATIONS
145	Incidence of Hepatitis C Virus Infections Among Users of Human Immunodeficiency Virus Pre-exposure Prophylaxis. Clinical Gastroenterology and Hepatology, 2022, 20, 674-681.	2.4	6
146	Reproducible radiographs of acetabular prostheses. Acta Orthopaedica, 1994, 65, 258-262.	1.4	5
147	Long-term outcomes of laparoscopic liver resection for hepatocellular carcinoma: A propensity score matched analysis of a high-volume North American center. Surgery, 2022, 171, 982-991.	1.0	5
148	Beyond Biochemical Responses, Use of Histologic Staging to Predict Outcomes of Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 1033-1035.	2.4	4
149	Continuous Interferon-α2B Infusion in Combination with Ribavirin for Chronic Hepatitis C in Treatment-Experienced Patients. Antiviral Therapy, 2012, 17, 509-517.	0.6	3
150	HBV DNA suppression in HBeAgâ€positive chronic hepatitis B patients treated with peginterferon or placebo. Journal of Medical Virology, 2011, 83, 1917-1923.	2.5	3
151	Sustained Virological Response to Treatment in Patients With Chronic Hepatitis C—Reply. JAMA - Journal of the American Medical Association, 2013, 309, 1457.	3.8	3
152	Psychological consequences of MRI-based screening among women with strong family histories of breast cancer. Breast Cancer Research and Treatment, 2021, 189, 497-508.	1.1	3
153	HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition. Clinical Gastroenterology and Hepatology, 2020, 18, 259-261.	2.4	2
154	Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon–ribavirin combination therapy after 4 weeks of treatment. European Journal of Gastroenterology and Hepatology, 2010, 22, 1.	0.8	2
155	Effect of blood group and HLA matching on pancreas graft survival with the use of UW solution. Transplant International, 1995, 8, 366-373.	0.8	2
156	High-dose (peg)interferon therapy in treatment-naÃ⁻ve, interleukin-28B rs12979860 CT/TT genotype 1 chronic hepatitis C. Digestive and Liver Disease, 2015, 47, 87-88.	0.4	1
157	Corrigendum to "Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B―[] Hepatol 37 (2002) 137–144]. Journal of Hepatology, 2002, 37, 708.	1.8	0
158	Editorial: liver transplantation for primary biliary cholangitis—the need for timely and more effective treatments. Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 473-474.	1.9	0